Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection
Copyright © 2012 Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 146(2013), 2 vom: 15. Feb., Seite 120-30 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2013
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Clinical Trial, Phase I Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Adjuvants, Immunologic Epitopes, T-Lymphocyte HLA-A Antigens HLA-B Antigens HLA-C Antigens Immunodominant Epitopes |
| Résumé: | Copyright © 2012 Elsevier Inc. All rights reserved. We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals |
|---|---|
| Description: | Date Completed 01.04.2013 Date Revised 04.02.2013 published: Print-Electronic ClinicalTrials.gov: NCT01009762 Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2012.12.005 |